Affiliations 

  • 1 Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
  • 2 Department of Otolaryngology, National Taiwan University Hospital and College of Medicine, Taipei City, Taiwan
  • 3 Outcomes Research, Regional Asia Pacific, MSD Thailand, Bangkok, Thailand
  • 4 Global Medical and Scientific Affairs, MSD Taiwan, Taipei, Taiwan
  • 5 HEOR & Market Access, OPEN Health, Bethesda, MD, USA
  • 6 HEOR & Market Access, OPEN Health, Shanghai, China
Hum Vaccin Immunother, 2024 Dec 31;20(1):2362449.
PMID: 38925146 DOI: 10.1080/21645515.2024.2362449

Abstract

There is limited literature on current human papillomavirus (HPV) vaccination in the Asia-Pacific region. This integrative literature review was conducted to describe HPV vaccination programs in Hong Kong, Indonesia, Japan, South Korea, Malaysia, the Philippines, Singapore, Taiwan, Thailand, and Vietnam. Program descriptions, recommendations, f unding, and coverage data were extracted. Twenty-five citations were included. As of 2022, eight of the 10 areas of interest include HPV in their national immunization program (NIP) for school-aged girls; full implementation in Indonesia is expected in 2023 whereas Vietnam's NIP does not include HPV. Singapore also includes HPV vaccination for women (18-26 years). None of the HPV vaccination programs include males. In most areas (n = 7), programs include only one vaccine option. While female HPV NIPs are present in the Asia-Pacific region, opportunities remain to strengthen NIPs in broader populations (e.g., males, catch-up cohorts) to expand public health impact and provide gender equity in HPV vaccination.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.